Alnylam

FDA Approves Eight Novel Drugs in August
FDA Approves Eight Novel Drugs in August
BioSpace
Kyowa Hakko Kirin
Poteligeo
Alnylam
Onpattro
Amicus Therapeutics
Galafold
TherapeuticMD
Annovera
Biocodex
Diacomit
Dompe Group
Oxervate
Shire
Takhzyro
Merck
Pifeltro
Flag link:
6 Things Alnylam Investors Need to Know About Pfizer's Next Blockbuster Drug
6 Things Alnylam Investors Need to Know About Pfizer's Next Blockbuster Drug
Motley Fool
Alnylam
Onpattro
Pfizer
ATTR amyloidosis
tafamidis
Vyndaqel
Flag link:
2 Blockbuster New Drug Launches Making Investors Nervous Right Now
2 Blockbuster New Drug Launches Making Investors Nervous Right Now
Motley Fool
drug launches
Alnylam
GW Pharma
Onpattro
Epidiolex
Flag link:
3 Things Alnylam's Management Wants Investors to Know About the Launch of Onpattro
3 Things Alnylam's Management Wants Investors to Know About the Launch of Onpattro
Motley Fool
Alnylam
Onpattro
hATTR amyloidosis
drug pricing
labeling
Flag link:
2 Reasons Alnylam Stock Fell on a Landmark Drug Approval
2 Reasons Alnylam Stock Fell on a Landmark Drug Approval
Motley Fool
Alnylam
FDA
Onpattro
hATTR amyloidosis
Flag link:
3 Hurdles Ahead of Alnylam and Its Revolutionary New Drug
3 Hurdles Ahead of Alnylam and Its Revolutionary New Drug
Motley Fool
Alnylam
Onpattro
RNAi
Flag link:
After Alnylam’s solo maiden launch, here comes the tricky bit
After Alnylam’s solo maiden launch, here comes the tricky bit
EP Vantage
Alnylam
drug launches
FDA
RNAi
Patisiran
Onpattro
Flag link:
Alnylam Prices First Gene Silencing Drug At $450,000 Per Patient, But Offers Money-Back Guarantee
Alnylam Prices First Gene Silencing Drug At $450,000 Per Patient, But Offers Money-Back Guarantee
Forbes
Alnylam
FDA
drug pricing
hATTR amyloidosis
Onpattro
Flag link:
In first, FDA approves RNA interference drug from Alnylam
In first, FDA approves RNA interference drug from Alnylam
Biopharma Dive
Alnylam
RNAi
FDA
Patisiran
Onpattro
hATTR amyloidosis
Flag link:
With patisiran launch in its sights, Alnylam plots a major hiring spree
With patisiran launch in its sights, Alnylam plots a major hiring spree
Fierce Pharma
Alnylam
Patisiran
RNAi
hirings
Flag link:
Alnylam Pharmaceuticals Is "Launch Ready"
Alnylam Pharmaceuticals Is "Launch Ready"
Motley Fool
Alnylam
FDA
Onpattro
TTRsc02
lumasiran
Flag link:
The Week Ahead In Biotech: Conferences, PDUFA Dates And IPOs
The Week Ahead In Biotech: Conferences, PDUFA Dates And IPOs
Yahoo/Benzinga
biotech
IPOs
Pain Therapeutics
Remoxy
Vertex Pharmaceuticals
lumacaftor/ivacaftor
Alnylam
Patisiran
Regeneron
Eylea
Insmed
Paratek
Vaccinex
Flag link:
The UK's MHRA Grants Early Access to Anlylam's Patisiran
The UK's MHRA Grants Early Access to Anlylam's Patisiran
CP Wire
Alnylam
Patisiran
hATTR amyloidosis
UK
Flag link:
The UK's MHRA Grants Early Access to Anlylam's Patisiran
Alnylam
Patisiran
hATTR amyloidosis
Flag link:
Alnylam Receives Positive CHMP Opinion for Hereditary Amyloidosis Treatment
Alnylam Receives Positive CHMP Opinion for Hereditary Amyloidosis Treatment
CP Wire
Alnylam
Patisiran
EMA
hATTR amyloidosis
Flag link:
Alnylam Receives Positive CHMP Opinion for Hereditary Amyloidosis Treatment
Alnylam
Patisiran
hATTR amyloidosis
Flag link:
Alnylam Presents Ph III results of Patisiran in Hereditary ATTR (hATTR) Amyloidosis
Alnylam Presents Ph III results of Patisiran in Hereditary ATTR (hATTR) Amyloidosis
CP Wire
Alnylam
Patisiran
hereditary ATTR amyloidosis
Flag link:
Alnylam Presents Ph III results of Patisiran in Hereditary ATTR (hATTR) Amyloidosis
Alnylam
hereditary ATTR amyloidosis
Patisiran
Flag link:
Poised to launch its first marketing effort, Alnylam makes a big leap into CNS diseases and Alzheimer’s
Poised to launch its first marketing effort, Alnylam makes a big leap into CNS diseases and Alzheimer’s
Endpoints
Alnylam
RNAi
Alzheimer's disease
Flag link:
FDA Extends Action Date on Akcea's Inotersen, Alnylam Now in Lead
FDA Extends Action Date on Akcea's Inotersen, Alnylam Now in Lead
CP Wire
Akcea
hereditary ATTR amyloidosis
FDA
inotersen
Alnylam
Patisiran
Flag link:

Pages